SRR934718
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 76.87253613666228
- age_years
- 25
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.470
- HEDGEHOG_SIGNALING+0.429
- G2M_CHECKPOINT+0.427
- E2F_TARGETS+0.409
- MYC_TARGETS_V2+0.373
- NOTCH_SIGNALING+0.360
- WNT_BETA_CATENIN_SIGNALING+0.345
- MITOTIC_SPINDLE+0.342
- OXIDATIVE_PHOSPHORYLATION+0.329
- PANCREAS_BETA_CELLS+0.305
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.325
- COAGULATION-0.324
- TNFA_SIGNALING_VIA_NFKB-0.314
- MYOGENESIS-0.298
- INTERFERON_GAMMA_RESPONSE-0.291
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.278
- IL2_STAT5_SIGNALING-0.275
- INFLAMMATORY_RESPONSE-0.272
- ALLOGRAFT_REJECTION-0.261
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.251
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A85A0E3A-2CB9-40EB-80E9-125EC137151B | — | — | 0.929 |
| 2 | 6E8A9288-C2F1-4DDE-B52B-7656DB802FB4 | — | — | 0.928 |
| 3 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.918 |
| 4 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.912 |
| 5 | 4D9EF242-9F58-4681-ADCF-556E05932931 | — | — | 0.905 |
| 6 | 93B9C99A-08DD-4F78-9CF5-C59A01605C9D | — | — | 0.902 |
| 7 | 2C70D7BF-85C4-447B-B0F9-A129D6B49E77 | — | — | 0.902 |
| 8 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.899 |
| 9 | 46BEFC7F-2F51-4331-BA86-9823EC5781B3 | — | — | 0.895 |
| 10 | 10FB7E59-9D71-4AB9-8D06-9CFD2304D1BC | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.429 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.427 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.409 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.373 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.345 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.342 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.329 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.305 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.273 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.221 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.203 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.188 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.179 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.168 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.152 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.078 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.049 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.035 | Idelalisib | — uncovered |